• Bao Yin, XiaoTong Jiang, XinFeng Chang, and ChunHua Song.
• Department of Cardiovascular, Zibo Hospital of Traditional Chinese Medicine, Zibo City, Shandong Province, China.
• Clinics (Sao Paulo). 2024 Jan 1; 79: 100496100496.

ObjectiveQiliqiangxin Capsule (QL) was investigated for its possible role in cardiac hypertrophy in this study.MethodsQL (0.5 mg/mL) was pre-treated in Neonatal Mouse Ventricular Cardiomyocytes (NMVCs) before induction of cardiomyocyte hypertrophy by Angiotensin II (Ang-II). Immunofluorescence staining for α-actinin was conducted to determine cell surface area. Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) of hypertrophy markers were examined. Ang-II infusion was given to stimulate cardiac hypertrophy in mice. The cardiac function of mice was detected by echocardiography, and the pathological status of myocardial tissue was observed.ResultsThe surface of cardiomyocytes was enlarged by Ang-II, and ANP and BNP levels were increased. QL processing could save these changes. miR-382-5p was upregulated in Ang-II-treated NMVCs, and reducing miR-382-5p could further enhance the therapeutic effect of QL while elevating miR-382-5p weakened the protective effect of QL. QL could inhibit miR-382-5p expression to negatively regulate Activated Transcription Factor 3 (ATF3) expression. Enhancing ATF3 expression rescued miR-382-5p upregulation-mediated role in NMVCs. In addition, QL alleviated Ang-II-stimulated cardiac hypertrophy and cardiac dysfunction in mice.ConclusionQL may alleviate cardiac hypertrophy and cardiac dysfunction via the miR-382-5p/ATF3 axis.Copyright © 2024 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.

34 keywords...

hide…